JP2023539125A5 - - Google Patents
Info
- Publication number
- JP2023539125A5 JP2023539125A5 JP2023512139A JP2023512139A JP2023539125A5 JP 2023539125 A5 JP2023539125 A5 JP 2023539125A5 JP 2023512139 A JP2023512139 A JP 2023512139A JP 2023512139 A JP2023512139 A JP 2023512139A JP 2023539125 A5 JP2023539125 A5 JP 2023539125A5
- Authority
- JP
- Japan
- Prior art keywords
- disorders
- disorder
- compound according
- exceeds
- salt form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063068222P | 2020-08-20 | 2020-08-20 | |
| US63/068,222 | 2020-08-20 | ||
| PCT/US2021/046935 WO2022040545A1 (en) | 2020-08-20 | 2021-08-20 | Organic compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023539125A JP2023539125A (ja) | 2023-09-13 |
| JP2023539125A5 true JP2023539125A5 (https=) | 2024-08-28 |
Family
ID=80350596
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023512139A Pending JP2023539125A (ja) | 2020-08-20 | 2021-08-20 | 有機化合物 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20230416300A1 (https=) |
| EP (1) | EP4200312A4 (https=) |
| JP (1) | JP2023539125A (https=) |
| WO (1) | WO2022040545A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA51046A (fr) | 2017-12-08 | 2021-03-17 | Sage Therapeutics Inc | Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc |
| US10562930B1 (en) | 2018-08-31 | 2020-02-18 | Praxis Precision Medicines, Inc. | Salts and crystal forms of GABAA positive allosteric modulator |
| MX2021007142A (es) | 2018-12-17 | 2021-08-11 | Intra Cellular Therapies Inc | Compuestos organicos. |
| EP4329751A4 (en) * | 2021-04-26 | 2025-03-19 | Praxis Precision Medicines, Inc. | Methods of treatment with neuroactive steroids |
| CN116606341A (zh) * | 2022-07-28 | 2023-08-18 | 上海醇健实业发展有限公司 | 治疗中枢神经系统疾病的甾体化合物及其制备方法、用途和药物组合物 |
| EP4650359A1 (en) * | 2022-07-28 | 2025-11-19 | Hunan Kyf Pharmaceutical. Co., Ltd. | Steroid compound for treating central nervous system disease, method for preparing same, and use and pharmaceutical composition thereof |
| WO2024059608A1 (en) * | 2022-09-15 | 2024-03-21 | Sage Therapeutics, Inc. | Deuterated neuroactive steroids |
| EP4711377A1 (en) * | 2023-05-11 | 2026-03-18 | Shujing Biopharma Co., Ltd | Steroid compound, preparation method therefor, and use thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5232917A (en) * | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
| ES2296594T3 (es) * | 1994-02-14 | 2008-05-01 | Euro-Celtique S.A. | Androstanos y pregnanos para la modulacion alosterica del receptor de gaba. |
| UA73736C2 (en) * | 1999-04-29 | 2005-09-15 | Euro Celtic S A | Method for alleviating or preventing insomnia and inducing anesthesia |
| CN117024501A (zh) * | 2014-10-16 | 2023-11-10 | 萨奇治疗股份有限公司 | 靶向cns障碍的组合物和方法 |
| EP3229350B1 (en) * | 2016-04-08 | 2021-06-23 | Black & Decker Inc. | Brushless motor for a power tool |
| MA51046A (fr) * | 2017-12-08 | 2021-03-17 | Sage Therapeutics Inc | Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc |
| MX2020006599A (es) * | 2017-12-22 | 2020-11-06 | Sage Therapeutics Inc | Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central. |
| MX2021007142A (es) * | 2018-12-17 | 2021-08-11 | Intra Cellular Therapies Inc | Compuestos organicos. |
| WO2021168106A1 (en) * | 2020-02-18 | 2021-08-26 | Praxis Precision Medicines, Inc. | Deuterated neurosteroid |
-
2021
- 2021-08-20 JP JP2023512139A patent/JP2023539125A/ja active Pending
- 2021-08-20 EP EP21859213.7A patent/EP4200312A4/en active Pending
- 2021-08-20 US US18/042,103 patent/US20230416300A1/en active Pending
- 2021-08-20 WO PCT/US2021/046935 patent/WO2022040545A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023539125A5 (https=) | ||
| JP2022513933A5 (https=) | ||
| JP2023527575A5 (https=) | ||
| JP2021519267A5 (https=) | ||
| CN100455560C (zh) | 含长链脂肪酰基取代的文拉法辛前体药物及其制备方法和用途 | |
| JP2022535093A (ja) | 重水素化された又は部分的に重水素化されたｎ，ｎ－ジメチルトリプタミン化合物を含む治療用組成物 | |
| JP2017531020A5 (https=) | ||
| CN113423686B (zh) | 氯胺酮双羟萘酸盐及其用途 | |
| RU2011119990A (ru) | Циклоалкиламины в качестве ингибиторов повторного поглощения моноамина | |
| US5552418A (en) | Trisubstituted Naphthylalkylamides | |
| RU2012127770A (ru) | Полициклические соединения и способы их применения | |
| JP2009527462A5 (https=) | ||
| JP2023509798A5 (https=) | ||
| JP2024531437A5 (https=) | ||
| JP2016525142A (ja) | １，７−ナフチリジン誘導体 | |
| SG190067A1 (en) | Trans-2-decenoic acid derivative and pharmaceutical agent containing the same | |
| JP2025501410A5 (https=) | ||
| JP2025501411A5 (https=) | ||
| CN113717133B (zh) | 3-酰胺基-n-芳基苯甲酰胺类化合物及应用 | |
| RU2021119458A (ru) | Органические соединения | |
| JP2006517941A (ja) | 不安症および双極性障害の処置のための、ｓ−１０−ヒドロキシ−１０，１１−ジヒドロ−カルバマゼピンの使用 | |
| HUE024560T2 (hu) | Pantenil-dokozahexanoát, valamint ennek alkalmazása szív-érrendszeri betegségek kezelésére és megelõzésére | |
| CA3118954C (en) | Ketamine pamoate and use thereof | |
| BR112021013340B1 (pt) | Sal de pamoato de cetamina e usos de uma composição farmacêutica compreendendo o referido sal | |
| RU2024126638A (ru) | Кристаллы производного витамина d или кристаллы его сольвата |